Cargando…

The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients

BACKGROUND: In Saudi Arabia, a diet for life policy has been adopted in the management of amino acid metabolism disorders for years. However, the specially designed low protein products/medical foods - which are one of the important treatment tools - were not available up until several years ago in...

Descripción completa

Detalles Bibliográficos
Autores principales: Handoom, Bedour, Megdad, Eman, Al-Qasabi, Dana, Al Mesned, Munirah, Hawary, Reem, Al-Nufiee, Samir, Al-Hassnan, Zuhair, Alsayed, Moeenaldeen Dia, Eldali, Abdelmoneim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363253/
https://www.ncbi.nlm.nih.gov/pubmed/30805535
http://dx.doi.org/10.1016/j.ijpam.2018.04.001
_version_ 1783393079959486464
author Handoom, Bedour
Megdad, Eman
Al-Qasabi, Dana
Al Mesned, Munirah
Hawary, Reem
Al-Nufiee, Samir
Al-Hassnan, Zuhair
Alsayed, Moeenaldeen Dia
Eldali, Abdelmoneim
author_facet Handoom, Bedour
Megdad, Eman
Al-Qasabi, Dana
Al Mesned, Munirah
Hawary, Reem
Al-Nufiee, Samir
Al-Hassnan, Zuhair
Alsayed, Moeenaldeen Dia
Eldali, Abdelmoneim
author_sort Handoom, Bedour
collection PubMed
description BACKGROUND: In Saudi Arabia, a diet for life policy has been adopted in the management of amino acid metabolism disorders for years. However, the specially designed low protein products/medical foods - which are one of the important treatment tools - were not available up until several years ago in Saudi Arabia (SA). Our aim was to measure the compliance and quality of life in patients affected with these disorders followed in the metabolic nutrition clinic at King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, SA. METHODOLOGY: We used a non-randomized retrospective/prospective study which utilized the growth parameters, biochemical data of patients plus questionnaires collected from patients and their family/caregivers. A total of n = 182 patients affected with selected amino acid metabolism disorders were enrolled. Some were excluded n = 84 for various reasons. Sample analyzed were: Phenylketonuria (PKU) (44), Maple Syrup Urine Disease (MSUD) (30), Tyrosinemia (TYR) (17) and Homocystinuria (HCU) (7). Tandem Mass Spectrometry (TMS) used to quantitate plasma amino acid concentrations. Data was obtained using (COMPLE) Microsoft-Access which was designed by the metabolic nutrition clinic at KFSH&RC-Riyadh. Student's paired t-test was used to investigate relationship between variables. RESULTS: The main findings were the improvement of selected amino acid levels pre and post the usage of medical foods. In PKU patients, the TMS Phenylalanine (PHE) levels post usage was significantly decreased (P value < .0001). This was also the case in MSUD patients with significant decrease in Leucine & Isoleucine levels (P value .0008) but not in Valine levels (P value .1148) as 36.7% of them received Valine supplements while enrolled in the study. CONCLUSION: Low protein products availability was successful in improving outcomes for selected amino acid metabolic disorders. However, due to compliance issues and impracticality of the diet, the results were not significant in all enrolled patients.
format Online
Article
Text
id pubmed-6363253
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher King Faisal Specialist Hospital and Research Centre
record_format MEDLINE/PubMed
spelling pubmed-63632532019-02-25 The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients Handoom, Bedour Megdad, Eman Al-Qasabi, Dana Al Mesned, Munirah Hawary, Reem Al-Nufiee, Samir Al-Hassnan, Zuhair Alsayed, Moeenaldeen Dia Eldali, Abdelmoneim Int J Pediatr Adolesc Med Original Research Article BACKGROUND: In Saudi Arabia, a diet for life policy has been adopted in the management of amino acid metabolism disorders for years. However, the specially designed low protein products/medical foods - which are one of the important treatment tools - were not available up until several years ago in Saudi Arabia (SA). Our aim was to measure the compliance and quality of life in patients affected with these disorders followed in the metabolic nutrition clinic at King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, SA. METHODOLOGY: We used a non-randomized retrospective/prospective study which utilized the growth parameters, biochemical data of patients plus questionnaires collected from patients and their family/caregivers. A total of n = 182 patients affected with selected amino acid metabolism disorders were enrolled. Some were excluded n = 84 for various reasons. Sample analyzed were: Phenylketonuria (PKU) (44), Maple Syrup Urine Disease (MSUD) (30), Tyrosinemia (TYR) (17) and Homocystinuria (HCU) (7). Tandem Mass Spectrometry (TMS) used to quantitate plasma amino acid concentrations. Data was obtained using (COMPLE) Microsoft-Access which was designed by the metabolic nutrition clinic at KFSH&RC-Riyadh. Student's paired t-test was used to investigate relationship between variables. RESULTS: The main findings were the improvement of selected amino acid levels pre and post the usage of medical foods. In PKU patients, the TMS Phenylalanine (PHE) levels post usage was significantly decreased (P value < .0001). This was also the case in MSUD patients with significant decrease in Leucine & Isoleucine levels (P value .0008) but not in Valine levels (P value .1148) as 36.7% of them received Valine supplements while enrolled in the study. CONCLUSION: Low protein products availability was successful in improving outcomes for selected amino acid metabolic disorders. However, due to compliance issues and impracticality of the diet, the results were not significant in all enrolled patients. King Faisal Specialist Hospital and Research Centre 2018-06 2018-06-14 /pmc/articles/PMC6363253/ /pubmed/30805535 http://dx.doi.org/10.1016/j.ijpam.2018.04.001 Text en © 2018 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Handoom, Bedour
Megdad, Eman
Al-Qasabi, Dana
Al Mesned, Munirah
Hawary, Reem
Al-Nufiee, Samir
Al-Hassnan, Zuhair
Alsayed, Moeenaldeen Dia
Eldali, Abdelmoneim
The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
title The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
title_full The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
title_fullStr The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
title_full_unstemmed The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
title_short The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
title_sort effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363253/
https://www.ncbi.nlm.nih.gov/pubmed/30805535
http://dx.doi.org/10.1016/j.ijpam.2018.04.001
work_keys_str_mv AT handoombedour theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT megdademan theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alqasabidana theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT almesnedmunirah theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT hawaryreem theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alnufieesamir theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alhassnanzuhair theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alsayedmoeenaldeendia theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT eldaliabdelmoneim theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT handoombedour effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT megdademan effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alqasabidana effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT almesnedmunirah effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT hawaryreem effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alnufieesamir effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alhassnanzuhair effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT alsayedmoeenaldeendia effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients
AT eldaliabdelmoneim effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients